Two reduced dose radiopharmaceutical therapy approaches for advanced stage metastatic castrate-resistant prostate cancer have been shown to be just as effective as the standard dose, according to new ...

Differential treatment effect on overall survival (OS) based on early prostate-specific antigen (PSA) response in metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of TITAN ...

Clinical study design and research outcomes. (Bottom left) Low dose abiraterone acetate (AA) demonstrated reduced PSA levels-a marker of tumour activity. (Bottom middle) Safety profile suggested that ...

This article was reviewed by Darragh O’Carroll, MD. Prostate-specific antigen (PSA) is a term you’ll probably become familiar with once you start getting screened regularly for prostate cancer ...

Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in certain cases. Active surveillance is increasingly chosen for favorable ...

WASHINGTON — Combining short-term androgen deprivation therapy (ADT) with high-dose radiotherapy improves disease-free survival in men with intermediate-risk prostate cancer compared with high-dose ...

The understanding of prostate cancer has significantly evolved in the past 15 years. Therefore, many people — including primary care providers — may not be aware of the current guidelines for prostate ...